Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy

Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy: Prospective Longitudinal Study Over 12 Months.

The purpose of this study is to assess changes of bone mineral density (BMD) at 12 months during the therapeutic management of patients with lymphoma.

Inclusion Criteria:

• Subjects aged 18 to 80 with lymphoma,
• Histological diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin lymphoma (NHL) of follicular or aggressive (large cell or other),
• Patients who have not yet started their chemotherapy or who have started for less than a month
• Patient has signed informed consent.

Exclusion Criteria:

• Pathological fractures at the time of initial diagnosis of lymphoma,
• Compression of neurological epidural,
• Patients receiving treatment for osteoporosis (including bisphosphonates, selective modulators of estrogen receptor, calcitonin and parathyroid hormone Teriparatide).
• Discovery of osteoporosis or osteopenia fracture during the initial evaluation requiring the establishment of an osteoporosis treatment,
• Radiotherapy to the lumbar spine or hip studied,
• Location of bone lymphoma in the lumbar spine or hip studied,
• History of disorders affecting bone metabolism (prostate cancer with androgen, stomach cancer, hyperparathyroidism, hyperthyroidism, uncontrolled ...)
• A person incapable of giving consent personally,
• Pregnant or breastfeeding women,
• Protected Person (under guardianship)
• Patient not affiliated with a social security system.